过去五十年的特点是神经退行性疾病激增。不幸的是,目前的治疗只是对症。因此,为治愈性治疗寻找新的和创新的治疗靶点成为一项重大挑战。在这些靶标中,腺苷A 2A受体(A 2A AR) 已成为近年来大量研究的主题。在本文中,我们报告了喹唑啉衍生物作为具有高配体效率的 A 2A AR 拮抗剂的设计、合成和药理学分析。这类分子是通过虚拟筛选发现的,与参考拮抗剂 ZM-241385 没有结构相似性。更准确地说,我们确定了一系列 2-氨基喹唑啉作为有前途的 A 2AAR拮抗剂。其中,一种化合物对A 2A AR ( 21a , K i = 20 nM)表现出高亲和力。我们将这种配体与 A 2A AR 复合结晶,证实了我们预测的对接姿势之一,并为进一步优化以获得特定腺苷受体亚型的选择性配体开辟了可能性。
[EN] HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QUE MODULATEURS DU TRANSPORT D'AMINES BIOGÈNES
申请人:ANANTHAN SUBRAMANIAM
公开号:WO2016090296A1
公开(公告)日:2016-06-09
The present disclosure relates to certain amine derivatives of fused bicyclic heterocycles that inhibit the amine reuptake function of the biogenic amine transporters, dopamine transporter (DAT), serotonin transporter (SERT) and norepinephrine transporter (NET). Compounds of the present disclosure are potent inhibitors of the reuptake of dopamine (DA), serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE) with full or partial maximal efficacy. The compounds with partial maximal efficacy in inhibiting reuptake of all three biogenic amines are herein referred to as partial triple uptake inhibitors (PTRIs). Compounds of the present disclosure are useful for treating depression, pain and substance abuse and relapse to substance abuse and addiction to substances such as cocaine, methamphetamine, nicotine and alcohol. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Discovery, Synthesis, and Evaluation of 2,4-Diaminoquinazolines as a Novel Class of Pancreatic β-Cell-Protective Agents against Endoplasmic Reticulum (ER) Stress
作者:Hongliang Duan、Jae Wook Lee、Sung Won Moon、Daleep Arora、Yu Li、Hui-Ying Lim、Weidong Wang
DOI:10.1021/acs.jmedchem.6b00041
日期:2016.9.8
progression of β-cell dysfunction and death. In diabetes, a major cause for the decline in β-cell function and survival is endoplasmic reticulum (ER) stress. Here, we identified quinazoline derivatives as a novel class of β-cell protective agents against ER stress-induced dysfunction and death. A series of quinazoline derivatives were synthesized from dichloroquiazoline utilizing a sequence of nucleophilic reactions
[EN] NOVEL QUINAZOLINES AS BIOGENIC AMINE TRANSPORT MODULATORS<br/>[FR] NOUVELLES QUINAZOLINES EN TANT QUE MODULATEURS DU TRANSPORT D'AMINES BIOGÈNES
申请人:ANANTHAN SUBRAMANIAM
公开号:WO2016090299A1
公开(公告)日:2016-06-09
The present disclosure relates to certain amine derivatives of fused bicyclic heterocycles that inhibit the amine reuptake function of the biogenic amine transporters, dopamine transporter (DAT), serotonin transporter (SERT) and norepinephrine transporter (NET). Compounds of the present disclosure are potent inhibitors of the reuptake of dopamine (DA), serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE) with full or partial maximal efficacy. The compounds with partial maximal efficacy in inhibiting reuptake of all three biogenic amines are herein referred to as partial triple uptake inhibitors (PTRIs). Compounds of the present disclosure are useful for treating depression, pain and substance abuse and relapse to substance abuse and addiction to substances such as cocaine, methamphetamine, nicotine and alcohol. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
2,4-DIAMINOQUINAZOLINE DERIVATIVES FOR INHIBITING ENDOPLASMIC RETICULUM (ER) STRESS
申请人:The Board of Regents of the University of Oklahoma
公开号:US20190047988A1
公开(公告)日:2019-02-14
Novel 2,4-diaminoquinazoline derivatives are disclosed. The compounds can be used in treating diseases and conditions which are associated with abnormal cell function related to endoplasmic reticulum (ER) stress. For example, the compounds can be used as suppressors of ER stress-induced pancreatic β-cell dysfunction and death, for example in the treatment of diabetes.
NOVEL QUINAZOLINES AS BIOGENIC AMINE TRANSPORT MODULATORS
申请人:ANANTHAN Subramaniam
公开号:US20160159751A1
公开(公告)日:2016-06-09
The present disclosure relates to certain amine derivatives of fused bicyclic heterocycles that inhibit the amine reuptake function of the biogenic amine transporters, dopamine transporter (DAT), serotonin transporter (SERT) and norepinephrine transporter (NET). Compounds of the present disclosure are potent inhibitors of the reuptake of dopamine (DA), serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE) with full or partial maximal efficacy. The compounds with partial maximal efficacy in inhibiting reuptake of all three biogenic amines are herein referred to as partial triple uptake inhibitors (PTRIs). Compounds of the present disclosure are useful for treating depression, pain and substance abuse and relapse to substance abuse and addiction to substances such as cocaine, methamphetamine, nicotine and alcohol. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.